Martin Jädersten

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BLOOD. 2024;144(11):1221-1229
Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes
Sirenko M; Bernard E; Creignou M; Domenico D; Farina A; Ossa JEA; Kosmider O; Hasserjian R; Jadersten M; Germing U; Sanz G; van de Loosdrecht AA; Gurnari C; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Sander B; Orna E; Zoldan K; Eder LN; Sperr WR; Thalhammer R; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Ogawa S; Fontenay M; Jansen JH; Cervera J; Ebert BL; Bejar R; Greenberg PL; Gattermann N; Malcovati L; Cazzola M; Beck DB; Hellstrom-Lindberg E; Papaemmanuil E
Article: JOURNAL OF INTERNAL MEDICINE. 2024;296(1):53-67
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes
Creignou M; Bernard E; Gasparini A; Tranberg A; Todisco G; Moura PL; Ejerblad E; Nilsson L; Garelius H; Antunovic P; Lorenz F; Rasmussen B; Walldin G; Mortera-Blanco T; Jansson M; Tobiasson M; Elena C; Ferrari J; Galli A; Pozzi S; Malcovati L; Edgren G; Crowther MJ; Jaedersten M; Papaemmanuil E; Hellstroem-Lindberg E
Article: JOURNAL OF CLINICAL ONCOLOGY. 2024;42(12):1378-1390
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation
Tobiasson M; Pandzic T; Illman J; Nilsson L; Westrom S; Ejerblad E; Olesen G; Bjorklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Lundstrom LY; von Bahr L; Baltzer-Sollander K; Jadersten M; Kytola S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellstrom-Lindberg E
Article: BLOOD ADVANCES. 2024;8(2):343-352
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML
Jimenez-Chillon C; Othman J; Taussig D; Jimenez-Vicente C; Martinez-Roca A; Tiong IS; Jain M; Aries J; Cakmak S; Knapper S; Kristensen DT; Murthy V; Galani JZ; Kallmeyer C; Ngu L; Veale D; Bolam S; Orfali N; Parker A; Manson C; Parker J; Erblich T; Richardson D; Mokretar K; Potter N; Overgaard UM; Roug AS; Wei AH; Esteve J; Jadersten M; Russell N; Dillon R
Article: BLOOD. 2024;143(3):233-242
Malignancy-associated hemophagocytic lymphohistiocytosis in Sweden: incidence, clinical characteristics, and survival
Lofstedt A; Jadersten M; Meeths M; Henter J-I
Journal article: BLOOD. 2023;142:1862
UBA1 Mutations Identify a Rare but Distinct Subtype of Myelodysplastic Syndromes
Sirenko M; Bernard E; Creignou M; Domenico D; Farina A; Ossa JEA; Kosmider O; Hasserjian R; Jadersten M; Germing U; Sanz G; van de Loosdrecht AA; Gurnari C; Follo MY; Thol F; Zamora L; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Ogawa S; Fontenay M; Jansen JH; Cervera J; Ebert BL; Bejar R; Greenberg PL; Gattermann N; Malcovati L; Cazzola M; Beck DB; Lindberg EH; Papaemmanuil E
Journal article: BLOOD. 2023;142:997
Molecular Taxonomy of Myelodysplastic Syndromes and Its Clinical Implications
Bernard E; Hasserjian R; Greenberg PL; Ossa JEA; Creignou M; Nannya Y; Tuechler H; Medina-Martinez JS; Levine MF; Jadersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Sirenko M; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Lindberg EH; Papaemmanuil E
Journal article: HEMASPHERE. 2023;7(Suppl):e93218cc
S173: RETROSPECTIVE STUDY OF LENALIDOMIDE DISCONTINUATION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME HARBORING DEL(5Q). A HARMONY ALLIANCE STUDY
Crisà E; Campelo MD; Germing U; Castera EM; Mohedo FH; Andrea K; Freja E; Myllymäki M; Jädersten M; Lindberg EH; Haase D; Capodanno I; Poloni A; Finelli C; Crugnola M; Fozza C; Calvisi A; Frairia C; Pietrantuono G; Cerrano M; Ciancia R; Barraco D; Hofmann W; Ruefer A; Bally C; Fenaux P; Santillana GS; Santini V
Journal article: HEMASPHERE. 2023;7(Suppl):e38749b6
P513: MOLECULAR PATTERN BY AGE AND OVERALL SURVIVAL IN ACUTE MYELOID LEUKEMIA: A POPULATION‐BASED STUDY FROM THE SWEDISH AML REGISTRY.
Juliusson G; Nilsson C; Lehmann S; Jädersten M; Wennström L; Fogelstrand L; Baliakas P; Pandzic T; Cavelier L; Eriksson A; Österroos A; Thunström A; Piauger B; Uggla B; Ölander E; Orrsjö G; Cammenga J; Myhr‐Eriksson K; Hjelm PW; Deneberg S; Fioretos T; Höglund M; Lazarevic V
Journal article: HEMASPHERE. 2023;7(Suppl):e790629d
P506: CLINICAL VALIDATION OF THE NORDIC GUIDELINES FOR GERMLINE TESTING IN MYELOID NEOPLASMS: RESULTS FROM A MULTI‐CENTER PROSPECTIVE COHORT STUDY
Tesi B; Eriksson A; Baskin B; Lazarevic V; Deneberg S; Höglund M; Fogelstrand L; Ungerstedt J; Pandzic T; Tobiasson M; Garelius HG; Kuchinskaya E; Persson F; Ågerstam H; Uggla B; Hallböök H; Fioretos T; Thuresson A; Lehmann S; Ladenvall C; Barbany G; Vennström L; Ejerblad E; Cavelier L; Cammenga J; Jädersten M; Lindberg EH; Baliakas P
Article: BLOOD. 2023;142(1):73-89
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option
Dolinska M; Cai H; Mansson A; Shen J; Xiao P; Bouderlique T; Li X; Leonard E; Chang M; Gao Y; Medina JP; Kondo M; Sandhow L; Johansson A-SF; Deneberg S; Soederlund S; Jaedersten M; Ungerstedt J; Tobiasson M; Ostman A; Mustjoki S; Stenke L; Le Blanc K; Hellstroem-Lindberg E; Lehmann S; Ekblom M; Olsson-Stroemberg U; Sigvarosson M; Qian H
Journal article: LEUKEMIA RESEARCH. 2023;128:107119
EARLY TRANSFUSION PATTERNS PREDICT OUTCOMES INDEPENDENTLY OF IPSS-M SCORE IN MYELODYSPLASTIC SYNDROMES
Creignou M; Bernard E; Crowther M; Tranberg A; Todisco G; Moura P; Ejerblad E; Nilsson L; Garelius H; Antunovic P; Lorenz F; Rasmussen B; Walldin G; Mortera-Blanco T; Jansson M; Tobiasson M; Edgren G; Jadersten M; Papaemmanuil E; Hellstrom-Lindberg E
Article: LEUKEMIA. 2023;37(5):1103-1112
Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective
Berggren DM; Garelius H; Hjelm PW; Nilsson L; Rasmussen B; Weibull CE; Lambe M; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ejerblad E
Journal article: CANCER RESEARCH. 2023;83(7_Supplement):6168
Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes
Bernard E; Ossa JEA; Tuechler H; Greenberg PL; Hasserjian RP; Nannya Y; Devlin SM; Creignou M; Pinel P; Monier L; Medina-Martinez JS; Domenico D; Jädersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Haase D; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FP; Boultwood J; Kotsianidis I; Santini V; Solé F; Platzbecker U; Heuser M; Valent P; Ohyashiki K; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Hellström-Lindberg E; Papaemmanuil E
Article: HAEMATOLOGICA. 2023;108(4):1015-1025
Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications
Nilsson C; Linde F; Hulegardh E; Garelius H; Lazarevic V; Antunovic P; Cammenga J; Deneberg S; Eriksson A; Jadersten M; Bjorkvall CK; Mollgard L; Wennstrom L; Olander E; Hoglund M; Juliusson G; Lehmann S
Article: SCIENCE IMMUNOLOGY. 2022;7(78):eadd3330
Notch-dependent cooperativity between myeloid lineages promotes Langerhans cell histiocytosis pathology
Kvedaraite E; Milne P; Khalilnezhad A; Chevrier M; Sethi R; Lee HK; Hagey DW; Greenwood TVB; Mouratidou N; Jadersten M; Lee NYS; Minnerup L; Tan Y; Dutertre C-A; Benac N; Hwang YY; Lum J; Loh AHP; Jansson J; Teng KWW; Khalilnezhad S; Xu W; Resteu A; Tey HL; Guan NL; Larbi A; Howland SW; Arnell H; Andaloussi SEL; Braier J; Rassidakis G; Galluzzo L; Dzionek A; Henter J-I; Chen J; Collin M; Ginhoux F
Article: JOURNAL OF INTERNAL MEDICINE. 2022;292(6):925-940
Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial
Jadersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzen S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Ostling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Hoglund M; Henter J-I; Herold N
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2022;198(4):721-728
Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma
Sveijer M; Greenwood TVB; Jadersten M; Kvedaraite E; Zetterberg H; Blennow K; Lourda M; Gavhed D; Henter J-I
Article: HAEMATOLOGICA. 2022;107(7):1528-1537
A risk score based on real-world data to predict early death in acute promyelocytic leukemia
Osterroos A; Maia T; Eriksson A; Jadersten M; Lazarevic V; Wennstrom L; Antunovic P; Cammenga J; Deneberg S; Lorenz F; Mollgard L; Uggla B; Olander E; Aguiar E; Trigo F; Hoglund M; Juliusson G; Lehmann S
Article: NEJM EVID. 2022;1(7):evidoa2200008
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Bernard E; Tuechler H; Greenberg PL; Hasserjian RP; Arango Ossa JE; Nannya Y; Devlin SM; Creignou M; Pinel P; Monnier L; Gundem G; Medina-Martinez JS; Domenico D; Jadersten M; Germing U; Sanz G; van de Loosdrecht AA; Kosmider O; Follo MY; Thol F; Zamora L; Pinheiro RF; Pellagatti A; Elias HK; Haase D; Ganster C; Ades L; Tobiasson M; Palomo L; Della Porta MG; Takaori-Kondo A; Ishikawa T; Chiba S; Kasahara S; Miyazaki Y; Viale A; Huberman K; Fenaux P; Belickova M; Savona MR; Klimek VM; Santos FPS; Boultwood J; Kotsianidis I; Santini V; Sole F; Platzbecker U; Heuser M; Valent P; Ohyashiki K; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Gattermann N; Ebert BL; Bejar R; Malcovati L; Cazzola M; Ogawa S; Hellstrom-Lindberg E; Papaemmanuil E
Journal article: HEMASPHERE. 2022;6:442-443
P543: TARGETING SAMHD1 WITH HYDROXYUREA IN FIRST‐LINE CYTARABINE‐BASED THERAPY OF NEWLY DIAGNOSED ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE HEAT‐AML TRIAL
Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore‐Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi R; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis G; Höglund M; Henter J; Herold N
Article: BONE MARROW TRANSPLANTATION. 2022;57(2):191-197
Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial
Walladbegi J; Henriksson R; Tavelin B; Svanberg A; Larfors G; Jadersten M; Schjesvold F; Mahdi A; Garming Legert K; Peterson DE; Jontell M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2021;27(12):991.e1-991.e9
Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic Prognostic Factors in a Nordic Population
Wedge E; Hansen JW; Dybedal I; Creignou M; Ejerblad E; Lorenz F; Werlenius O; Ungerstedt J; Holm MS; Nilsson L; Kittang AO; Antunovic P; Rohon P; Andersen MK; Papaemmanuil E; Bernard E; Jadersten M; Hellstrom-Lindberg E; Gronbaek K; Ljungman P; Friis LS
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2021;107(2):219-228
Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes
Larfors G; Moreno Berggren D; Garelius H; Jadersten M; Nilsson L; Rasmussen B; Ejerblad E
Article: LEUKEMIA & LYMPHOMA. 2021;62(8):1973-1981
Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study
Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf A; Deneberg S; Jadersten M; Antunovic P; Cammenga J; Mollgard L; Wennstrom L; Olander E; Ehinger M; Fogelstrand L; Hoglund M; Lazarevic VL
Article: NATURE COMMUNICATIONS. 2021;12(1):2474
A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia
Docking TR; Parker JDK; Jadersten M; Duns G; Chang L; Jiang J; Pilsworth JA; Swanson LA; Chan SK; Chiu R; Nip KM; Mar S; Mo A; Wang X; Martinez-Hoyer S; Stubbins RJ; Mungall KL; Mungall AJ; Moore RA; Jones SJM; Birol I; Marra MA; Hogge D; Karsan A
Article: ACTA PAEDIATRICA. 2021;110(4):1315-1321
Patients with both Langerhans cell histiocytosis and Crohn's disease highlight a common role of interleukin-23
Kvedaraite E; Lourda M; Han H; Tesi B; Mitchell J; Idestrom M; Mouratidou N; Rassidakis G; Greenwood TVB; Cohen-Aubart F; Jadersten M; Akefeldt SO; Svensson M; Kannourakis G; Bryceson YT; Haroche J; Henter J-I
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2021;192(3):474-483
Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study
Berggren DM; Kjellander M; Backlund E; Engvall M; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ungerstedt J; Ejerblad E
Article: NATURE MEDICINE. 2020;26(10):1549-1556
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Bernard E; Nannya Y; Hasserjian RP; Devlin SM; Tuechler H; Medina-Martinez JS; Yoshizato T; Shiozawa Y; Saiki R; Malcovati L; Levine MF; Arango JE; Zhou Y; Sole F; Cargo CA; Haase D; Creignou M; Germing U; Zhang Y; Gundem G; Sarian A; van de Loosdrecht AA; Jadersten M; Tobiasson M; Kosmider O; Follo MY; Thol F; Pinheiro RF; Santini V; Kotsianidis I; Boultwood J; Santos FPS; Schanz J; Kasahara S; Ishikawa T; Tsurumi H; Takaori-Kondo A; Kiguchi T; Polprasert C; Bennett JM; Klimek VM; Savona MR; Belickova M; Ganster C; Palomo L; Sanz G; Ades L; Della Porta MG; Smith AG; Werner Y; Patel M; Viale A; Vanness K; Neuberg DS; Stevenson KE; Menghrajani K; Bolton KL; Fenaux P; Pellagatti A; Platzbecker U; Heuser M; Valent P; Chiba S; Miyazaki Y; Finelli C; Voso MT; Shih L-Y; Fontenay M; Jansen JH; Cervera J; Atsuta Y; Gattermann N; Ebert BL; Bejar R; Greenberg PL; Cazzola M; Hellstrom-Lindberg E; Ogawa S; Papaemmanuil E
Journal article: EXPERIMENTAL HEMATOLOGY. 2020;88:s72
3108 – MOLECULAR MECHANISMS OF LENALIDOMIDE RESISTANCE IN DEL(5Q) MYELODYSPLASTIC SYNDROMES
Martinez-Høyer S; Deng Y; Parker J; Jiang J; Docking R; Mo A; Gharaee N; Jädersten M; Kulasekararaj A; Malcovati L; List A; Hellström-Lindberg E; Platzbecker U; Karsan A
Article: NATURE CELL BIOLOGY. 2020;22(5):526-533
Loss of lenalidomide-induced megakaryocytic differentiation leads to therapy resistance in del(5q) myelodysplastic syndrome
Martinez-Hoyer S; Deng Y; Parker J; Jiang J; Mo A; Docking TR; Gharaee N; Li J; Umlandt P; Fuller M; Jadersten M; Kulasekararaj A; Malcovati L; List AF; Hellstrom-Lindberg E; Platzbecker U; Karsan A
Article: BLOOD ADVANCES. 2020;4(6):1094-1101
The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting
Juliusson G; Jadersten M; Deneberg S; Lehmann S; Mollgard L; Wennstrom L; Antunovic P; Cammenga J; Lorenz F; Olander E; Lazarevic VL; Hoglund M
Article: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2019;8:7
The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016
Carlsten M; Jadersten M; Hellstrom A; Littmann K; Melen CM; Junlen HR; Sonnevi K; Ljungman P; Bjorkstrand B; Wahlin BE
Article: PLOS ONE. 2019;14(2):e0212812
PCR with electrospray ionization-mass spectrometry on bronchoalveolar lavage for detection of invasive mold infections in hematological patients
Krifors A; Ozenci V; Ullberg M; Ackefors M; Jadersten M; Stralin K; Blennow O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;181(5):614-627
Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register
Berggren DM; Folkvaljon Y; Engvall M; Sundberg J; Lambe M; Antunovic P; Garelius H; Lorenz F; Nilsson L; Rasmussen B; Lehmann S; Hellstrom-Lindberg E; Jadersten M; Ejerblad E
Article: HAEMATOLOGICA. 2017;102(3):498-508
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations
Scharenberg C; Giai V; Pellagatti A; Saft L; Dimitriou M; Jansson M; Jadersten M; Grandien A; Douagi I; Neuberg DS; LeBlanc K; Boultwood J; Karimi M; Jacobsen SEW; Woll PS; Hellstrom-Lindberg E
Journal article: BLOOD. 2016;128(22):4329
Progression in Patients with with Low- and Intermediate-1 Risk Del(5q) MDS Is Predicted By a Limited Subset of Mutations
Scharenberg C; Woll PS; Giai V; Pellagatti A; Saft L; Dimitriou M; Jädersten M; Jansson M; Douagi I; Neuberg DS; Karimi M; Le Blanc K; Boultwood J; Jacobsen SE; Hellstrom-Lindberg E
Article: ONCOTARGET. 2016;7(16):22103-22115
Mutations in histone modulators are associated with prolonged survival during azacitidine therapy
Tobiasson M; McLornan DP; Karimi M; Dimitriou M; Jansson M; Ben Azenkoud A; Jadersten M; Lindberg G; Abdulkadir H; Kulasekararaj A; Ungerstedt J; Lennartsson A; Ekwall K; Mufti GJ; Hellstrom-Lindberg E
Article: BLOOD. 2015;126(2):233-241
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts
Malcovati L; Karimi M; Papaemmanuil E; Ambaglio I; Jadersten M; Jansson M; Elena C; Galli A; Walldin G; Della Porta MG; Raaschou-Jensen K; Travaglino E; Kallenbach K; Pietra D; Ljungstrom V; Conte S; Boveri E; Invernizzi R; Rosenquist R; Campbell PJ; Cazzola M; Lindberg EH
Article: NATURE COMMUNICATIONS. 2015;6:5901
Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes
Gerstung M; Pellagatti A; Malcovati L; Giagounidis A; Della Porta MG; Jaedersten M; Dolatshad H; Verma A; Cross NCP; Vyas P; Killick S; Hellstroem-Lindberg E; Cazzola M; Papaemmanuil E; Campbell PJ; Boultwood J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(28):3557-3564
Identification of Gene Expression-Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes
Pellagatti A; Benner A; Mills KI; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Verma A; McDonald E-J; Killick S; Hellstrom-Lindberg E; Bullinger L; Wainscoat JS; Boultwood J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2013;31(21):2662-2670
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
Koreth J; Pidala J; Perez WS; Deeg HJ; Garcia-Manero G; Malcovati L; Cazzola M; Park S; Itzykson R; Ades L; Fenaux P; Jadersten M; Hellstrom-Lindberg E; Gale RP; Beach CL; Lee SJ; Horowitz MM; Greenberg PL; Tallman MS; DiPersio JF; Bunjes D; Weisdorf DJ; Cutler C
Journal article: BLOOD. 2012;120(21):3857
Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes
Pellagatti A; Benner A; Mills KI; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Verma A; McDonald E-J; Killick S; Hellstrom-Lindberg E; Bullinger L; Wainscoat JS; Boultwood J
Journal article: BLOOD. 2011;118(21):790
Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
Scharenberg C; Giai V; Pellagatti A; Saft L; Karlsson G; Jansson M; Forsblom L; Jadersten M; Karlsson S; Boultwood J; Hellstrom-Lindberg E
Article: HAEMATOLOGICA. 2011;96(7):963-971
Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities
Mollgard L; Saft L; Treppendahl MB; Dybedal I; Norgaard JM; Astermark J; Ejerblad E; Garelius H; Dufva IH; Jansson M; Jadersten M; Kjeldsen L; Linder O; Nilsson L; Vestergaard H; Porwit A; Gronbaek K; Lindberg EH
Article: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(15):1971-1979
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Jaedersten M; Saft L; Smith A; Kulasekararaj A; Pomplun S; Goehring G; Hedlund A; Hast R; Schlegelberger B; Porwit A; Hellstrom-Lindberg E; Mufti GJ
Journal article: LEUKEMIA RESEARCH. 2011;35:s101-s102
259 The clonal advantage of del(5q) MDS stem cells is mediated by increased adhesion to the microenvironment
Scharenberg C; Giai V; Jädersten M; Forsblom L; Jansson M; Hellström-Lindberg E
Journal article: LEUKEMIA RESEARCH. 2011;35:S7
18 Prognostic impact of TP53 mutations in MDS with del(5q)
Jadersten M
Journal article: BLOOD. 2010;116(21):298
Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Killick S; Vyas P; Hellström-Lindberg E; Boultwood J; Wainscoat JS
Article: LEUKEMIA. 2010;24(9):1607-1616
Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34⁺ blasts in myelodysplastic syndrome
Carlsten M; Baumann BC; Simonsson M; Jadersten M; Forsblom A-M; Hammarstedt C; Bryceson YT; Ljunggren H-G; Hellstrom-Lindberg E; Malmberg K-J
Article: LEUKEMIA. 2010;24(4):756-764
Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Killick S; Verma A; Norbury CJ; Hellstrom-Lindberg E; Wainscoat JS; Boultwood J
Article: HAEMATOLOGICA. 2009;94(12):1762-1766
Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
Jadersten M; Saft L; Pellagatti A; Goehring G; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellstrom-Lindberg E
Journal article: BLOOD. 2009;114(22):419
Frequent Mutation of the Polycomb-Associated Gene ASXL1 in the Myelodysplastic Syndromes and in Acute Myeloid Leukaemia.
Boultwood J; Perry J; Pellagatti A; Giagounidis A; Malcovati L; Della Porta MG; Jädersten M; Killick S; Hellström-Lindberg E; Cazzola M; Wainscoat JS
Journal article: BLOOD. 2009;114(22):735
Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells.
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jädersten M; Killick S; Verma A; Hellström-Lindberg E; Wainscoat JS; Boultwood J
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;146(1):86-90
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes
Pellagatti A; Marafioti T; Paterson JC; Malcovati L; Della Porta MG; Jadersten M; Pushkaran B; George TI; Arber DA; Killick S; Giagounidis A; Hellstrom-Lindberg E; Cazzola M; Wainscoat JS; Boultwood J
Journal article: BLOOD. 2008;112(11):5104
Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression
Jädersten M; Saft L; Pellagatti A; Göhring G; Fernández-Santamaria C; Wainscoat JS; Boultwood J; Porwit A; Schlegelberger B; Hellström-Lindberg E
Journal article: BLOOD. 2008;112(11):3642
Gene Expression Profiling of CD34+ Cells in Patients with Myelodysplastic Syndromes
Pellagatti A; Cazzola M; Giagounidis A; Perry J; Malcovati L; Della Porta M; Jädersten M; Killick S; Hellström-Lindberg E; Wainscoat JS; Boultwood J
Journal article: BLOOD. 2008;112(11):3641
Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)
Pellagatti A; Hellström-Lindberg E; Giagounidis A; Perry J; Malcovati L; Della Porta M; Jädersten M; Killick S; Sohal DP; Verma A; Cazzola M; Wainscoat JS; Boultwood J
Article: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(21):3607-3613
Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome
Jadersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit A; Cazzola M; Hellstrom-Lindberg E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;142(1):57-64
Haploinsufficiency of RPS14 in 5q-syndrome is associated with deregulation of ribosomal- and translation-related genes
Pellagatti A; Hellstrom-Lindberg E; Giagounidis A; Perry J; Malcovati L; Della Porta MG; Jadersten M; Killick S; Fidler C; Cazzola M; Wainscoat JS; Boultwood J
Article: PLOS ONE. 2008;3(4):e1970
The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts
Boultwood J; Pellagatti A; Nikpour M; Pushkaran B; Fidler C; Cattan H; Littlewood TJ; Malcovati L; Della Porta MG; Jadersten M; Killick S; Giagounidis A; Bowen D; Hellstrom-Lindberg E; Cazzola M; Wainscoat JS
Journal article: BLOOD. 2007;110(11):2427
Gene Expression Profiling of Day 7 Erythroblasts from RARS Before and after Treatment with G-CSF.
Nikpour M; Pellagatti A; Jädersten M; Forsblom A-M; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2007;139(4):578-589
Gene expression profiling of CD34⁺ cells in patients with the 5q-syndrome
Boultwood J; Pellagatti A; Cattan H; Lawrie CH; Giagounidis A; Malcovati L; Della Porta MG; Jaedersten M; Killick S; Fidler C; Cazzola M; Hellstroem-Lindberg E; Wainscoat JS
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2007;104(27):11406-11411
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients
Pellagatti A; Jaedersten M; Forsblom A-M; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Helistroem-Lindberg E
Article: CANCER CONTROL. 2006;13 Suppl:17-25
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.
Goss TF; Szende A; Schaefer C; Totten PJ; Knight R; Jädersten M; Hellström-Lindberg E; List AF
Journal article: BLOOD. 2006;108(11):855
Lenalidomide Up-Regulates SPARC and Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome Patients with 5q Deletion.
Pellagatti A; Jädersten M; Forsblom A-M; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Journal article: BLOOD. 2006;108(11):521
Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need.
Jädersten M; Malcovati L; Dybedal I; Della Porta MG; Invernizzi R; Montgomery SM; Pascutto C; Porwit-MacDonald A; Cazzola M; Hellström-Lindberg E
Journal article: BLOOD. 2005;106(11):3438
Lenalidomide Selectively Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome (MDS) Patients with 5q Deletion.
Jädersten M; Pellagatti A; Forsblom A-M; Emanuelsson EK; Merup M; Samuelsson J; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Article: CLINICAL CANCER RESEARCH. 2005;11(17):6291-6299
Antiapoptotic role of growth factors in the Myelodysplastic syndromes: Concordance between in vitro and in vivo observations
Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom AM; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hollström-Lindberg E
Journal article: LEUKEMIA RESEARCH. 2005;29:s6
O-17 Thalidomide analogue CC5013 (revlimid) selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5Q deletion
Jadersten M; Forsblom A-M; Emanuelsson EK; Merup M; Hellström-Lindberg E
Journal article: IMMUNOLOGY LETTERS. 1994;40(2):111-115
BIPHASIC EFFECT OF TRANSFORMING GROWTH-FACTOR-BETA ON EPSTEIN-BARR VIRUS-INDUCED ACTIVATION OF HUMAN TONSILLAR B-CELLS
ALTIOK A; JADERSTEN M; MAGYARLAKI T; KLEIN E
Visa fler

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2023-2026

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2008
Läkarexamen, Karolinska Institutet, 2000

Artiklar

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI